Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-Fresenius S for GvHD Prophylaxis in Stem Cell Transplantation
NCT00655343Phase 3Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Feb 2003
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of grafalon in graft-versus-host disease (GVHD), sponsored by Neovii Pharmaceuticals. Started Feb 2003; status: completed.
02
Drugs
grafalon
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00655343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655343.